AERI - Aerie inks licensing deal for Rhopressa and Rocklatan in Europe and several other regions

Aerie Pharmaceuticals (NASDAQ:AERI) and Santen (OTC:SNPHF) have entered into an exclusive development and commercialization agreement for Rhopressa/Rhokiinsa (netarsudil ophthalmic solution) 0.02% and Rocklatan/Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expanded collaboration includes Europe, Commonwealth of Independent States (CIS) countries, China, India, parts of Latin America and the Oceania countries. This is an expansion from AERI's initial collaboration with Santen for Japan and East Asia, announced in October 2020. Under the terms of the agreement, Aerie will receive an upfront payment of $88M, and various development, regulatory and sales milestones of up to $77M. Aerie is also eligible to receive additional consideration in excess of 25% of the products’ net sales, such consideration consisting of the cost of products supplied to Santen from Aerie and a royalty for Aerie’s intellectual property. Santen will be responsible for sales, marketing and pricing decisions relating to the products and for all development and commercialization

For further details see:

Aerie inks licensing deal for Rhopressa and Rocklatan in Europe and several other regions